Only a day earlier, Genzyme Corp. pulled out of the litigation as part of a settlement. Genzyme and Mount Sinai School of Medicine claimed that Transkaryotic's main product, Replagal, infringed on one of their patents.

A Delaware district court dismissed the lawsuit in January 2002, and Genzyme and Mount Sinai appealed the decision in March of that year.